36 results about "Tumor-Free Margins" patented technology

Embodiments of the invention provide a system and method for resecting a tissue mass. The system for resecting a tissue mass includes a surgical instrument and a first sensor for measuring a signal corresponding to the position and orientation of the tissue mass. The first sensor is dimensioned to fit insider or next to the tissue mass. The system also includes a second sensor attached to the surgical instrument configured to measure the position and orientation of the surgical instrument. The second sensor is configured to receive the signal from the first sensor. A controller is in communication with the first sensor and / or the second sensor, and the controller executes a stored program to calculate a distance between the first sensor and the second sensor. Accordingly, visual, auditory, haptic or other feedback is provided to the clinician to guide the surgical instrument to the surgical margin.

An instrument used for brachytherapy delivery in the treatment of cancer by radiation therapy including a handle having first and second handle actuators; an end effector; and an instrument shaft that connects the handle with the end effector. The end effector has first and second adjacent disposed staple mechanisms that each retain a set of staples. The first mechanism is for holding standard staples in a first array, and dispensing the standard staples under control of the corresponding first handle actuator. The second mechanism is for holding radioactive source staples in a second array, and dispensing said radioactive source staples under control of the corresponding second handle actuator. A holder is for receiving the first and second mechanisms in a substantially parallel array so that the standard staples close the incision at a surgical margin while the source staples are secured adjacent thereto.

Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including seminal vesicle involvement, surgical margin involvement, lymph node status, androgen receptor (AR) staining index of tumor, a morphometric measurement of epithelial nuclei, and at least one morphometric measurement of stroma. In another embodiment, a model that predicts clinical failure post prostatectomy is provided, wherein the model is based on features including biopsy Gleason score, lymph node involvement, prostatectomy Gleason score, a morphometric measurement of epithelial cytoplasm, a morphometric measurement of epithelial nuclei, a morphometric measurement of stroma, and intensity of androgen receptor (AR) in racemase (AMACR)-positive epithelial cells.

A method, using high intensity ultrasound, which may also be combined with a chemotherapy agent, that can result the direct destruction of tumor cells and in the reduction or elimination of local reoccurrence of cancer after removal of cancerous tissue, such as a surgical breast lumpectomy or surgical excision of a brain tumor. The method comprises either (1) the treatment of the tumor directly with High Intensity Focused Ultrasound, or (2) the treatment of the margins of the tissue surrounding the surgical cavity or void with ablative continuous wave high intensity ultrasound and a combination of a locally delivered chemotherapy agent and high intensity ultrasound, termed sonoporation. The present invention permits both the direct destruction (ablation) of tumor tissue as well as the destruction of tissue around the surgical margin and may include the enhanced local cellular uptake of locally injected chemotherapeutic drugs, all of which can be accomplished by a therapeutic ultrasound device used during surgery.

Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including seminal vesicle involvement, surgical margin involvement, lymph node status, androgen receptor (AR) staining index of tumor, a morphometric measurement of epithelial nuclei, and at least one morphometric measurement of stroma. In another embodiment, a model that predicts clinical failure post prostatectomy is provided, wherein the model is based on features including biopsy Gleason score, lymph node involvement, prostatectomy Gleason score, a morphometric measurement of epithelial cytoplasm, a morphometric measurement of epithelial nuclei, a morphometric measurement of stroma, and intensity of androgen receptor (AR) in racemase (AMACR)-positive epithelial cells.

An instrument used for brachytherapy delivery in the treatment of cancer by radiation therapy including a handle having first and second handle actuators; an end effector; and an instrument shaft that connects the handle with the end effector. The end effector has first and second adjacent disposed staple mechanisms that each retain a set of staples. The first mechanism is for holding standard staples in a first array, and dispensing the standard staples under control of the corresponding first handle actuator. The second mechanism is for holding radioactive source staples in a second array, and dispensing said radioactive source staples under control of the corresponding second handle actuator. A holder is for receiving the first and second mechanisms in a substantially parallel array so that the standard staples close the incision at a surgical margin while the source staples are secured adjacent thereto.

The present invention in one aspect relates to a method for surgical margin evaluation of tissues during breast conserving therapy at a surgical site of interest. In one embodiment, the method comprises the steps of acquiring a plurality of spatially offset Raman spectra from the surgical site of interest, identifying tissue signatures from the plurality of spatially offset Raman spectra, and determining surgical margins of the surgical site from the identified tissue signatures.

An instrument used for brachytherapy delivery in the treatment of cancer by radiation therapy including a handle having first and second handle actuators; an end effector; and an instrument shaft that connects the handle with the end effector. The end effector has first and second adjacent disposed staple mechanisms that each retain a set of staples. The first mechanism is for holding standard staples in a first array, and dispensing the standard staples under control of the corresponding first handle actuator. The second mechanism is for holding radioactive source staples in a second array, and dispensing said radioactive source staples under control of the corresponding second handle actuator. A holder is for receiving the first and second mechanisms in a substantially parallel array so that the standard staples close the incision at a surgical margin while the source staples are secured adjacent thereto.

A method and device for applying a radioactive source to a tissue site is disclosed. The device facilitates the precise placement of, for example, 125Iodine seeds relative to the surgical margin, assures the seeds remain fixed in their precise position for the duration of the treatment, overcomes the technical difficulties of manipulating the seeds through the narrow surgical incision, and reduces the radiation dose to the clinicians. The device incorporates the radioactive seeds into a fastening means, preferably surgical staples, used in the surgical procedure. In this way, the seeds are concurrently secured in position directly adjacent to the surgical resection and remain immobile.

A method and device for applying a radioactive source to a tissue site is disclosed. The device facilitates the precise placement of, for example, 125Iodine seeds relative to the surgical margin, assures the seeds remain fixed in their precise position for the duration of the treatment, overcomes the technical difficulties of manipulating the seeds through the narrow surgical incision, and reduces the radiation dose to the clinicians. The device incorporates the radioactive seeds into a fastening means, preferably surgical staples, used in the surgical procedure. In this way, the seeds are concurrently secured in position directly adjacent to the surgical resection and remain immobile.

The present invention relates to methods and medicaments useful for the treatment of brain tumors by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments are provided for reducing tumor cell proliferation and tumor growth, reducing tumor vascularity, inhibiting tumor cell invasion, improving tumor surgical margins and prolonging survival of patients with brain tumors.

A skin biopsy punch has a transparent cutting edge, allowing a user to view a patient's skin in and around a portion to be cut. In one embodiment, the cutting edge allows viewing of a skin lesion and the lesion's margins. By viewing the margins, the lesion may be cleanly removed or excised with a higher rate of negative or clear surgical margins.

A mobile compact imaging system that combines both of the imaging system of and optical imaging into a single system which can be located in the operating room (OR) and provides faster feedback to determine if a tumor has been fully resected and if there are adequate surgical margins. While final confirmation is obtained from the pathology lab, such a device can reduce the total time necessary for the procedure and the number of iterations required to achieve satisfactory resection of a tumor with good margins.

Among other aspects, the present invention provides biomarkers and methods of identifying precancerous fields in a subject in need thereof. Methods of diagnosing and for providing a prognosis for a subject with an increased risk of developing cancer are also provided, along with methods of determining surgical margins for a tumor or tissue resection procedure. Additionally, reagents and kits are provided for the practice of the methods disclosed herein.

A source delivery surgical staple device delivers a source / seed to a staple margin. The surgical staple delivery device includes a main staple body segment hingedly attached to a second body segment. Each of the segments is appointed for engagement to dispense the sources / seeds for the treatment of microscopic disease to a surgical margin. The device also includes a cartridge removably attached and snapped onto the main staple body segment. The cartridge has a source / seed / brachy staple line forming a brachy or radioactive seeds and / or chemotherapy agent dosage source. The radioactive seeds have a radioactive and / or chemotherapy source supported by leg portions that are manipulated during insert for fastening the radioactive staples to tissue at an incision margin. A hybrid of chemotherapy agent and radiation is delivered directly into the surgical margin and different dosage can be loaded in the cartridge.

The present invention relates to the detection of field cancerization by detection of aberrations in tumor target genes at the margins of resected tumors, and the use of such information to predict survival in cancer patients. Methods for treatment of cancer based thereon also are provided.

The present invention in one aspect relates to a method for surgical margin evaluation of tissues during breast conserving therapy at a surgical site of interest. In one embodiment, the method comprises the steps of acquiring a plurality of spatially offset Raman spectra from the surgical site of interest, identifying tissue signatures from the plurality of spatially offset Raman spectra, and determining surgical margins of the surgical site from the identified tissue signatures.

Embodiments of the invention provide a system and method for resecting a tissue mass. The system for resecting a tissue mass includes a surgical instrument and a first sensor for measuring a signal corresponding to the position and orientation of the tissue mass. The first sensor is dimensioned to fit insider or next to the tissue mass. The system also includes a second sensor attached to the surgical instrument configured to measure the position and orientation of the surgical instrument. The second sensor is configured to receive the signal from the first sensor. A controller is in communication with the first sensor and / or the second sensor, and the controller executes a stored program to calculate a distance between the first sensor and the second sensor. Accordingly, visual, auditory, haptic or other feedback is provided to the clinician to guide the surgical instrument to the surgical margin.

Embodiments of the invention provide a system and method for resecting a tissue mass. The system for resecting a tissue mass includes a surgical instrument and a first sensor for measuring a signal corresponding to the position and orientation of the tissue mass. The first sensor is dimensioned to fit inside or next to the tissue mass. The system also includes a second sensor attacked to the surgical instrument configured to measure the position and orientation of the surgical instrument. The second sensor is configured to receive the signal from the first sensor. A controller is in communication with the first sensor and / or the second sensor, and the controller executes a stored program to calculate a distance between the first sensor and the second sensor. Accordingly, visual, auditory, haptic or other feedback is provided to the clinician to guide the surgical instrument to the surgical margin.

A method for treating cancer. The method comprises treating a patient having a cancerous tumor with a gene inhibitor pre-operatively to inhibit upregulation of a particular gene, surgically removing the cancerous tumor, treating the patient with the gene inhibitor intra-operatively to inhibit upregulation of a particular gene, applying cold atmospheric plasma to surgical margins around the area in the patient from which the tumor was surgically removed, and treating the patient with the gene inhibitor post-operatively.

A method of assessing surgical margins is disclosed. The method includes, subsequent to administration of a compound configured to induce emissions of between about 600 nm and about 660 nm in cancerous tissue cells, positioning a distal end of a handheld, white light and fluorescence-based imaging device adjacent to a surgical margin. The method also includes, with the handheld device, substantially simultaneously exciting and detecting autofluorescence emissions of tissue cells and fluorescence emissions of the induced wavelength in tissue cells of the surgical margin. And, based on a presence or an amount of fluorescence emissions of the induced wavelength detected in the tissue cells of the surgical margin, determining whether the surgical margin is substantially free of at least one ofprecancerous cells, cancerous cells, and satellite lesions. The compound may be a non-activated, non-targeted compound such as ALA.

An imaging system and method are disclosed for intraoperative surgical margin assessment in between various tissues and cell groupings having differing physiologic processes. The system uses an arrayof LED's to pump a target anatomy with a short excitation pulse and measures the lifetime of fluorescence to generate contrast. A relative fluorescence lifetime map is generated corresponding to the measured lifetime to identify boundaries within varying cell groupings and tissues.

A small, mobile imaging system that combines both imaging and optical imaging into a single system that can be located in the operating room (OR) and provide rapid feedback to determine whether a tumor has been adequately resected and whether there is Adequate surgical margins. Such a device may reduce the overall time required for the procedure and reduce the number of iterations required to achieve satisfactory resection of the tumor with good margins, although final confirmation is still to be obtained from the pathology laboratory.

Currently most cancers, including breast cancers, are removed without any intraoperative margin control. Post-operative methods inspect 1-2% of the surgical margin and are prone to sampling errors. The present invention relates to an optical imaging system that will enable evaluation of the surgical margin in vivo and in real-time. The invention provides for simultaneous fluorescence and fluorescence polarization imaging. The contrast of the acquired images will be enhanced using fluorescent agents approved for diagnostic use in patients. As the staining pattern of fluorescence images is similar to that of histology, and the values of fluorescence polarization are significantly higher in cancerous as compared to normal cells, the invention provides for further improvements in diagnostic methods. The systems and methods can be applied to the intra-operative delineation of cancerous tissue.

The invention belongs to the field of optical molecule imaging, in particular to an intraoperative tissue cherenkov fluorescence imaging system and an image processing method thereof. The problems that the material collection area of intraoperative frozen pathologic slices is small and the analysis time is long are solved. The system disclosed by the invention comprises a light source module, an information acquisition module, and a central control module, wherein the light source module is used for emitting white light irradiated intraoperative tissues; the information acquisition module is used for acquiring colored white light images, gray-scale white light images and cherenkov fluorescence images of the intraoperative tissues; the central control module is used for controlling the light source module to lighten and controlling the information acquisition module to acquire the images and receive the state information of the light source module and image information acquired by the information acquisition module; and the intraoperative tissue images are generated through a built-in image processing algorithm. According to the imaging system disclosed by the invention, spontaneoussignals are produced during imaging, a signal-to-background ratio is high, and an imaging process is high in specificity, high in sensitivity, high in resolution ratio of a shallow layer and high inimaging speed; and moreover, surgical margin testing of the intraoperative tissues can be quickly and effectively realized.

Embodiments of the invention provide a system and method for resecting a tissue mass. The system for resecting a tissue mass includes a first sensor for measuring a signal corresponding to the position and orientation of the tissue mass. The first sensor is dimensioned to fit inside of or next to the tissue mass. The system also includes a second sensor attached to a surgical instrument configured to measure the position and orientation of the surgical instrument. A controller is in communication with the first sensor and the second sensor, and the controller executes a stored program to calculate a distance between the first sensor and the second sensor. Accordingly, visual, auditory, haptic or other feedback is provided to the clinician to guide the surgical instrument to the surgical margin.

A method for a method for treatment of cholangiocarcinoma (CCA) with cold atmospheric plasma and Folfirinox. The method includes treating a patient having CCA with a low dosage FOLFIRINOX regimen, for example, 6.73 nM, giving the patient the low-dosage FOLFIRINOX regimen pre-operatively, surgically removing the cancerous tumor from the patient, continuing the low-dosage FOLFIRINOX treatment regimen intra-operatively, applying cold atmospheric plasma to the surgical margins surrounding the area in the patient from which the tumor was removed, and continuing the FOLFIRINOX post-operatively.